MediGene Obtains US Patent on EndoTAG™-1
Martinsried/Munich – San Diego, September 28, 2006. Today the German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announced that the US patent office has granted a patent covering the drug candidate EndoTAGTM-1. The patent protects the substance EndoTAGTM-1 developed by MediGene as a drug for the treatment of various types of cancer.
Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: “The patent on the composition of the substance adds another pivotal component to MediGene’s protection for EndoTAGTM-1. This cements the unique position of the product by a broad patent portfolio, an excellent starting point to make the promising drug candidate EndoTAGTM-1 a commercial success.”
MediGene has exclusively licensed the newly issued patent no. US 7,112,338 from the University of California, San Francisco. Further patent applications regarding the manufacturing process and administration of the drug have also been filed by MediGene AG. In addition, MediGene holds several patents on the EndoTAGTM technology in general.
EndoTAGTM aims at a novel method of cancer therapy by “starving out” tumors. EndoTAGTM-1 combines the established active substance Paclitaxel with an innovative carrier system of positively charged lipid complexes. They allow a transport of the substance specifically to the negatively charged newly developed tumor blood vessels. There the drug is discharged in order to destroy the blood vessels, thus suppressing the tumor’s nutrient supply. MediGene is currently conducting an extensive clinical phase II trial of EndoTAGTM-1 for the treatment of pancreatic cancer. Another clinical phase II trial in the indication hormone-resistant breast cancer is scheduled for initiation at the end of 2006. Apart from that, MediGene is also examining the application of the EndoTAGTM technology for the treatment of other diseases.
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene and TMEndoTAGTM are trademarks of MediGene AG.
- Ends -
MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried, Germany and San Diego, USA. MediGene is the first German biotech company with a drug on the market. The NDA for a second drug, Polyphenon® E Ointment, is under review by the FDA. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies. The company’s core competence lies in research and development of novel approaches in anti cancer therapies. Thus MediGene focuses on indications of high medical need and great economic opportunities.
- Contact Information
- Dr. Georg Dönges
- Public Relations
- MediGene AG
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.